Exclusive Summary

• Original product patents have definitively expired globally, leaving zero intellectual property barriers for immediate distribution and commercial engagement in emerging markets.
• The flexible 100mg dosage exerts dual clinical benefits regarding anti-depression and mild psychiatric stabilization, catering to stable, uncompromising demand from over 300 million chronic patients globally.
• Capitalizing on China's fully integrated API-to-formulation manufacturing supply chain, it boasts formidable pricing advantages seamlessly aligned with the aggressive cost-control mandates of public procurement tenders worldwide.
• Supported by exhaustive and structured registration documentation (e.g., CTD-format dossiers), enabling overseas distribution partners to clear regulatory hurdles swiftly and lock in lucrative market shares effortlessly.